Phenotypic Drug Discovery Conference to Deliver New Insight for Better Target and Drug Selection

NEEDHAM, Mass. - July 16, 2013 - PRLog -- Cambridge Healthtech Institute announces the final agenda for Phenotypic Drug Discovery, a two-day conference designed to address the advantages of phenotypic vs. target-based screening. The meeting is set to bring together global drug discovery teams to discuss case studies, examples and analysis on the disproportionate number of first-in-class drugs with novel mechanisms of action coming from phenotypic screening. Presentations will focus on assay development, selection of physiologically-relevant models and subsequent target identification.

Featured presentations include:

The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines
David C. Swinney, Ph.D., CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3)

Systematic Repositioning of Drugs Using Phenotypic Screening Data
Mark Hurle, Ph.D., Senior Investigator, Bioinformatics and Computational Biology, GlaxoSmithKline

The Role of HCA in Quantitative Systems Pharmacology
D. Lansing Taylor, Ph.D., Director, University of Pittsburgh Drug Discovery Institute and Allegheny Foundation; Professor, Computational and Systems Biology, University of Pittsburgh

Phenotypic Screening and Profiling in Increasingly Physiologically-Relevant Contexts
Anne Carpenter, Ph.D., Director, Imaging Platform, Broad Institute

Expanding the Use of Primary Cell Systems in Hit Identification and Compound Profiling
Steve Ludbrook, Ph.D., Section Head, Screening and Compound Profiling, GlaxoSmithKline

Phenotypic Screening for Lipid Droplet Modulators
Zhuyin (Julie) Li, Ph.D., Biology Team Leader, Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, NIH

The conference will be held October 28-29, 2013 in Cambridge, MA as part of Cambridge Healthtech Institute’s FAST: Functional Analysis & Screening Technologies Congress.  To view the final agenda, speaking faculty, program abstracts and registration details, visit http://www.fastcongress.com/Phenotypic-Drug-Discovery.

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), founded in 1992, is the industry leader in providing superior quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations.  Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.